AstraZeneca strengthens cancer business with new deals
LONDON (Reuters) – AstraZeneca moved to strengthen its core oncology business on Tuesday with three deals designed to expand the British drugmaker's reach in treating tumors. The collaborations include an agreement to buy Definiens, a private company that has developed a way of unlocking information from cancer tissue samples, for an initial $150 million, and two alliances to test novel drug combinations. Definiens, whose imaging and data analysis technology was developed by Gerd Binnig, the 1986 Nobel Laureate in physics, will be folded into AstraZeneca's biotech arm MedImmune. …